Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the safety and efficacy of TRx0237 in the
treatment of patients with behavioral variant frontotemporal dementia (bvFTD).